PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland.\', \'Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.\', \'Department of Biochemistry, University of Washington, Seattle, WA 98195, USA; Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, 75015 Paris, France.\', \'Vir Biotechnology, San Francisco, CA 94158, USA.\', \'Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.\', \'Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.\', \'Division of Primary Care, Geneva University Hospitals, 1205 Geneva, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland.\', \'Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.\', \'III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.\', \'Independent Physician, 6500 Bellinzona, Switzerland.\', \'Institute of Public Health, Università della Svizzera italiana, 6900 Lugano, Switzerland.\', \'Faculty of Biomedical Sciences, Università della Svizzera italiana, 6900 Lugano, Switzerland; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.\', \'Division of Infectious Diseases, Ente Ospedaliero Cantonale, Ospedale Civico and Ospedale Italiano, 6900 Lugano, Switzerland.\', \'Division of Infectious Diseases, Ente Ospedaliero Cantonale, Ospedale Regionale Bellinzona e Valli and Ospedale Regionale, 6600 Locarno, Switzerland.\', \'Department of Nephrology, Ospedale Civico Lugano, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland; Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, NSW 2052, Australia.\', \'Humabs BioMed SA, Vir Biotechnology, 6500 Bellinzona, Switzerland. Electronic address: dcorti@vir.bio.\', \'Department of Biochemistry, University of Washington, Seattle, WA 98195, USA. Electronic address: dveesler@uw.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0092-8674(20)31234-410.1016/j.cell.2020.09.037
?:doi
?:hasPublicationType
?:journal
  • Cell
is ?:pmid of
?:pmid
?:pmid
  • 32991844
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 25.137
?:rankingScore_hIndex
  • 682
is ?:relation_isRelatedTo_publication of
?:title
  • Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32991844>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32991844>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all